Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
BRAF V600 Colorectal Cancer
Conditions
BRAF V600 Colorectal Cancer
Trial Timeline
Jul 22, 2020 → Sep 25, 2024
NCT ID
NCT04294160About Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab
Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab is a phase 1 stage product being developed by Novartis for BRAF V600 Colorectal Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04294160. Target conditions include BRAF V600 Colorectal Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04294160 | Phase 1 | Terminated |
Competing Products
13 competing products in BRAF V600 Colorectal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PLX3397 + vemurafenib | Daiichi Sankyo | Phase 1 | 33 |
| TMZ + E7016 | Eisai | Phase 2 | 52 |
| Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil | Ono Pharmaceutical | Phase 3 | 77 |
| encorafenib + Binimetinib + Cetuximab | Ono Pharmaceutical | Phase 2 | 52 |
| Encorafenib + Cetuximab + FOLFIRI | Merck | Phase 2 | 52 |
| Tafinlar/Mekinist | Novartis | Pre-clinical | 23 |
| BKM120 Combined with Vemurafenib (PLX4032) | Novartis | Phase 1/2 | 41 |
| Cobimetinib + Atezolizumab + Pembrolizumab | Roche | Phase 3 | 77 |
| LGX818 + MEK162 + LEE011 | Pfizer | Phase 1/2 | 40 |
| MEK162 | Pfizer | Phase 2 | 51 |
| Encorafenib + Binimetinib + cemiplimab+fianlimab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Plixorafenib + Cobicistat 150 MG [Tybost] | Brain Biotech | Phase 1 | 25 |
| Dabrafenib + Trametinib + Hydroxychloroquine | Brain Biotech | Phase 1/2 | 33 |